Global And China Catheter Market, By Product Type (Cardiovascular Catheter, Urology Catheters, Intravenous Catheters, Neurovascular Catheters, Specialty Catheters), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jul 2023

Code : CMI4010

Pages :180

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Global And China Catheter Market: Key Developments

On May 19, 2023 Abbott Laboratories, announced that the U.S. Food and Drug Administration (FDA) has approved the company’s TactiFlex Ablation Catheter, Sensor Enabled, the world’s first ablation catheter with a flexible tip and contact force technology. it is used to perform an ablation procedure to treat atrial fibrillation (AFib), the most common abnormal heart rhythm.

In February 2022, Medtronic plc, is a healthcare technology company, announced that the Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters are the first and only ablation catheters approved by the U.S. Food and Drug Administration (FDA) to treat the growing prevalence of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).

In October 2020, Cardinal Health, a cardiovascular and endovascular solutions company, announced several strategic distribution agreements that will enable Cordis, a Cardinal Health’s interventional vascular business, to rapidly expand its product portfolio in select countries globally. These distribution agreements, which add coronary stents and percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, expand Cordis’ portfolio of innovative products that support the treatment of patients undergoing percutaneous coronary intervention (PCI) from access to intervention and closure.

In December 2022, Medtronic plc, a medical technology company, announced the completion of enrollment and final treatment in the SPHERE Per-AF Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial designed to evaluate the safety and effectiveness of the first-of-its kind Sphere-9 pulsed field (PF) and radiofrequency (RF) ablation, and high density (HD) mapping catheter with the Affera cardiac mapping and navigation platform for the treatment of persistent atrial fibrillation (AF).